JNGHF — Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
—
OTC ·
Unknown ·
Unknown ·
CIK 2071868 ·
China
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
No quarterly fundamentals indexed for this ticker.
Balance + Analyst (yfinance extras)
Retained Earnings
$42,455,623,061
Inventory
$2,886,056,361
Receivables
—
ST Investments
$108,916,478
EBIT TTM
$9,917,521,709
Pretax Income TTM
$9,903,414,008
Interest Exp TTM
$14,107,702
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$32,564,369,408
EBITDA
$9,452,852,224
Free Cash Flow
$6,307,738,624
Enterprise Value
$7,611,628,032
Total Cash
$40,635,797,504
Total Debt
$67,474,744
Shares Out
—
Trailing EPS
—
Book Value
$1.39
ROE
14.5%
ROA
8.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 31,629,416,194 | 8,596,411,752 | 7,711,054,812 | 69,867,315,774 | 8,070,492,359 | — | 11,235,378,131 |
| Dec 2024 | 27,984,605,342 | 6,803,132,569 | 6,336,527,015 | 50,135,645,304 | 4,045,394,571 | — | 7,422,753,039 |
| Dec 2023 | 22,819,784,741 | 4,625,728,312 | 4,302,435,930 | 43,784,506,636 | 2,751,420,194 | — | 7,643,665,075 |
| Dec 2022 | 21,275,270,682 | 3,344,720,696 | 3,906,375,067 | 42,370,875,898 | 3,957,967,303 | — | 1,265,264,632 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SPY | SPDR S&P 500 ETF TRUST | $700.70B | $763.47 | — |
| QQQ | INVESCO QQQ TRUST, SERIES 1 | $277.65B | $706.32 | — |
| KLAC | KLA CORP | $237.23B | $181.57 | — |
| TMO | THERMO FISHER SCIENTIFIC INC. | $232.47B | $628.74 | — |
| IBM | INTERNATIONAL BUSINESS MACHINES CORP | $217.67B | $231.04 | — |
News headlines (Yahoo Finance, 1h cache)
Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease
2026-06-30 05:00 · Yahoo
Hengrui Pharma Reports Steady Growth in Q3 2025 Driven by Innovation and Global Expansion
2025-10-27 11:34 · Yahoo
Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)
2025-09-24 11:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.